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Abstract
Many beneficial proprieties have been associated with polyphenols from green tea, such as chemopreventive,
anticarcinogenic, antiatherogenic and antioxidant actions. In this study, we investigated the effects of green tea polyphenols
(GTPs) and their principal catechins on the function of P-glycoprotein (P-gp), which is involved in the multidrug resistance
phenotype of cancer cells. GTPs (30 Wg/ml) inhibit the photolabeling of P-gp by 75% and increase the accumulation of
rhodamine-123 (R-123) 3-fold in the multidrug-resistant cell line CHRC5, indicating that GTPs interact with P-gp and inhibit
its transport activity. Moreover, the modulation of P-gp transport by GTPs was a reversible process. Among the catechins
present in GTPs, EGCG, ECG and CG are responsible for inhibiting P-gp. In addition, EGCG potentiates the cytotoxicity
of vinblastine (VBL) in CHRC5 cells. The inhibitory effect of EGCG on P-gp was also observed in human Caco-2 cells, which
form an intestinal epithelial-like monolayer. Our results indicate that, in addition to their anti-cancer properties, GTPs and
more particularly EGCG inhibit the binding and efflux of drugs by P-gp. Thus, GTPs or EGCG might be potential agents for
modulating the bioavailability of P-gp substrates at the intestine and the multidrug resistance phenotype associated with
expression of this transporter in cancer cells. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
P-glycoprotein (P-gp) was ¢rst studied in the con-
text of cancer research where its overexpression in
tumor cells has been associated with the multidrug
resistance (MDR) phenotype [1^3]. In cancer cells,
P-gp acts as an e¥ux pump that extrudes chemo-
therapeutic agents out of the cells, decreasing their
intracellular concentration. This ATP-dependent
transporter also exports a wide variety of struc-
turally unrelated compounds such as vinka alka-
loids, antibiotics, anthracyclines, etoposides, cyto-
kines, opioids and steroids [3^8]. P-gp is also
expressed in normal tissues. High levels of P-gp ex-
pression have been observed in the endothelial cells
of brain capillaries, in kidney and in adrenal glands
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while moderate expression has been detected in
lung, liver and intestines [9^13]. P-gp is involved
in organism detoxi¢cation by excreting toxic com-
pounds into the bile, urine and gastrointestinal
tract [14^16]. Moreover, it seems to play an im-
portant role in brain protection at the blood-brain
barrier [14,17]. Localized at the luminal side of
endothelial cells in brain capillaries, P-gp pre-
vents the passage of many drugs into the brain
[18,19].
Recently, many groups have studied the bene¢cial
e¡ects of natural products in cancer prevention or
treatment. Studies have suggested that polyphenols
from green tea could have chemopreventive, anti-
atherogenic, anticarcinogenic and antioxidant pro-
prieties [20]. Epidemiological studies suggest a
chemopreventive e¡ect of green tea against breast,
prostate, esophagus, stomach, pancreas and colon
cancers [20^22]. Moreover, green tea consumption
in animal models inhibits cancer angiogenesis [23]
and metastasis [24], and reduced tumor forma-
tion in skin, lung, liver, pancreas and the gastro-
intestinal tract [20,21]. However, nothing is known
about the e¡ects of polyphenols from green tea on
the activity of P-gp. Green tea contains many
polyphenolic compounds. Flavanols, also called
catechins, are the major polyphenols found in
green tea. Six catechins are present in green tea,
the most abundant being (3)-epigallocatechin
gallate (EGCG) followed by (3)-epicatechin gallate
(ECG), (3)-epigallocatechin (EGC), (3)-epicatechin
(EC), (3)-catechin gallate (GC) and (+)-catechin (C)
[25].
In the present study, we investigated the e¡ects of
green tea polyphenols (GTPs) and the six principal
catechins of GTPs on P-gp function. Photoa⁄nity
labeling experiments using [125I]iodoarylazidoprazo-
sin (IAAP) show that GTPs interact with P-gp.
More speci¢cally, the catechins EGCG, ECG and
CG interact with P-gp. Furthermore, GTPs and the
principal catechin of green tea, EGCG, inhibit the
transport of two P-gp substrates, R-123 and
[3H]VBL, into both Chinese hamster ovary resistant
cells (CHRC5) and human colon adenocarcinoma
cells (Caco-2). These results suggest that GTPs and
EGCG, which interact with P-gp and inhibit its
transport activity, could be used to modulate the
function of P-gp.
2. Materials and methods
2.1. Materials
Sensitive (AuxB1) and resistant (CHRC5) cell lines
were provided by Dr. V. Ling and were grown in K-
MEM from Gibco BRL (Burlington, ON, Canada)
with 10% calf serum from HyClone Laboratories
(Logan, UT, USA). Caco-2 human colon adenocar-
cinoma cells were purchased from ATCC (Rockville,
MD, USA). Caco-2 cells were grown in DMEM high
glucose (Gibco BRL) containing 10 mg/l transferrin,
110 mg/l pyruvate and 10% calf serum from HyClone
Laboratories. Electrophoresis reagents were pur-
chased from BioRad (Mississauga, ON, Canada).
MAb C219, directed against P-gp, was from ID
Labs (London, ON, Canada). Anti-mouse IgG
horseradish peroxidase-linked whole antibody was
purchased from Jackson ImmunoResearch Labora-
tories (West Grove, PA, USA) and enhanced chem-
iluminescence (ECL) reagents were from Amersham
Pharmacia Biotech (Baie d’Urfe¤e, QC, Canada).
[125I]Iodoarylazidoprazosin (IAAP) (2200 Ci/mmol)
and [14C]sucrose (671 mCi/mmol) were purchased
from NEN (Boston, MA, USA) whereas
[3H]vinblastine (VBL) (11.3 Ci/mmol) was from
Amersham Pharmacia Biotech (Oakville, ON). Cy-
closporin A and PSC 833 were provided by Novartis
(Basel, Switzerland). Green tea polyphenols (GTPs)
were purchased from LKT Laboratories (St-Paul,
MN, USA) and catechins were purchased from Fu-
nakoshi Co (Tokyo, Japan), Sigma-Aldrich Canada
(Oakville, ON, Canada) and from ICN Biomedicals
(Aurora, OH, USA). All other reagents were from
Sigma^Aldrich Canada (Oakville, ON).
2.2. Photoa⁄nity labeling with [125I]IAAP
Membranes from CHRC5 cells were prepared as
described previously [26]. CHRC5 membranes (50
Wg) were incubated with 20 nM IAAP (2.3 WCi) in
10 mM Tris^HCl (pH 7.5) for 1 h at 25‡C in the
dark with 0.1% DMSO (control), verapamil (50
WM), cyclosporin A (5 WM), PSC 833 (5 WM), resver-
atrol (100 WM), GTPs (30 Wg/ml) or catechins (50
WM). The membranes were cross-linked under an
UV Stratalinker 2400 lamp (Stratagene, La Jolla,
CA, USA) at 254 nm for 5 min at 4‡C. Laemmli
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electrophoresis bu¡er (62.5 mM Tris^HCl (pH 6.8),
10% glycerol, 2% SDS, 5% L-mercaptoethanol,
0.01% bromophenol blue) was added to the mem-
brane samples and the proteins were resolved by
SDS^PAGE on 6.25% acrylamide/bisacrylamide
(29.2:0.8) gels. The gels were dried and the photo-
labeled P-gp was detected following exposure of the
gels to Fuji ¢lms for 1^3 h at 380‡C.
2.3. Rhodamine-123 accumulation
CHRC5 cells were seeded at 130 000 cells per well
in 24-well plates and cultured for 3 days at 37‡C and
5% CO2. At con£uence, cells were washed twice with
Hank’s balanced salt solution (HBSS) (1.3 mM
CaCl2, 5.4 mM KCl, 0.44 mM KH2PO4, 0.5 mM
MgCl2, 0.83 mM MgSO4, 137 mM NaCl, 4.2 mM
NaHCO3, 0.34 mM Na2HPO4 and 25 mM D-glucose,
pH 6.5) at 37‡C. Cells were pre-incubated 30 min
at 37‡C with HBSS containing DMSO (0.1% v/v)
or tested compounds (30 and 100 Wg/ml GTPs,
100 WM catechins, 5 WM CsA, 5 WM PSC 833,
50 WM verapamil or 100 WM resveratrol). R-123
(20 WM) was then added for an incubation of
2 h at 37‡C. R-123 accumulation was stopped by
washing the cells ¢ve times with cold phosphate-
bu¡ered saline (PBS) (150 mM NaCl, 2.7 mM KCl,
1.3 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4)
and the cells were lysed with 0.1% Triton X-100
at room temperature. Fluorescence of R-123 in cell
lysates was measured using a spectro£uorometer
(SpectraMax Gemini, Molecular Devices) at a wave-
length of 485 nm for excitation and 538 nm for emis-
sion.
2.4. E¥ux of Rhodamine-123
At con£uence, CHRC5 cells in 24-well plates were
washed twice with HBSS and incubated 2 h at 37‡C
with 20 WM R-123 and 10 WM CsA in order to load
the cells with R-123. Cells were then washed ¢ve time
with HBSS, following which HBSS containing 100
WM EGCG, 10 WM CsA, 10 WM PSC 833 or 0.1%
DMSO was added. After incubation at 37‡C for 0 to
60 min, cells were washed ¢ve times with cold PBS
and lysed with 0.1% Triton X-100 at room temper-
ature. The £uorescence of R-123 in cell lysates was
measured as described above.
2.5. Analysis of catechins in green tea polyphenols
The proportions of the individual catechins CG,
ECG and EGCG in green tea polyphenol extracts
were analyzed by high-performance liquid chroma-
tography (HPLC) on a C18 column with an isocratic
mobile phase composed of CH3CN/C2H2OCOCH3/
0.05% H3PO4 (12:0.6:90). For each catechin, a stan-
dard curve was made and its percentage (w/w) of
green tea polyphenols was calculated.
2.6. P-gp detection
P-gp was immunodetected by Western blot analy-
sis. Proteins from CHRC5 or AuxB1 cells were resus-
pended in Laemmli electrophoresis bu¡er without
prior heating, loaded and separated on 7.5% acryl-
amide/bisacrylamide (29.2:0.8) SDS^PAGE gels.
Gels were electroblotted onto PVDF membranes us-
ing standard procedures. Blots were blocked over-
night in Tris-bu¡ered saline (TBS: 147 mM NaCl,
20 mM Tris^HCl, pH 7.5) containing 0.3% Tween
20 and 5% non-fat dry milk followed by a 1 h 30
min incubation with the primary antibody against P-
gp (mAb C219) as described previously [12]. Blots
were washed three times with TBS containing 0.3%
Tween 20 followed by a 1 h incubation with horse-
radish peroxidase-conjugated antibodies directed
against mouse IgGs. Blots were again washed three
times with TBS and 0.3% Tween 20, and detection
was performed with ECL reagents (Amersham) ac-
cording to the manufacturer’s instructions.
2.7. Cell proliferation assay
CHRC5 or AuxB1 cells were seeded at 5000 and
3000 cells per well, respectively, in 96-well plates.
Varying concentrations of EGCG (0^50 WM) with
or without VBL (0^100 WM) were added and cells
were grown for 3 days at 37‡C and 5% CO2. To
measure cell proliferation, a crystal violet assay was
used. Brie£y, the cells were washed three times with
PBS and incubated 5 min at room temperature with
0.2% crystal violet in 10% ethanol. The crystal violet
stain was removed and the plate was washed three
times with PBS. Cells were lysed with 2% SDS and
absorbance was read at 560 nm with a spectropho-
tometer (ThermoMax, Molecular Devices).
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2.8. Vinblastine transport and accumulation in
Caco-2 cells
Apical-to-basal transport of VBL across a mono-
layer of Caco-2 cells was measured in the presence of
P-gp or MRP inhibitors. The intracellular accumula-
tion of VBL in Caco-2 cells was also measured and
the passage of sucrose across monolayers was used to
verify the integrity of the monolayer barrier during
all experiments. Caco-2 cells were seeded at 1500
cells per ¢lter (Transwell, 24 mm diameter, 0.4 Wm
pore size, Costar, Cambridge, MA, USA) in six-well
plates and cultured at 37‡C and 5% CO2. At the 20th
day of culture, Caco-2 cells were used for the experi-
ment. The transepithelial resistance, measured with
an epithelial voltohmmeter (World Precision Instru-
ments, Sarasota, FA, USA), was generally 800 6/
cm2. All of the experiments were performed at
37‡C. Caco-2 cell ¢lters were washed with HBSS
and transferred into fresh six-well plates containing
3 ml of HBSS. In the upper chamber of each ¢lter,
1 ml of HBSS with 20 nM [3H]VBL (0.23 WCi) or
74.5 nM [14C]sucrose (0.05 WCi) with or without
EGCG (100 WM), PSC 833 (10 WM) or indomethacin
(10 WM). After 30 and 60 min, ¢lters were moved
into fresh wells to limit basal-to-apical £ux. After
120 min, ¢lters were placed into fresh six-well plates,
washed three times with cold PBS and the polyester
membranes containing Caco-2 cells were removed
and placed into vials containing 10 ml of scintillation
cocktail solution in order to quantify the [3H]VBL
accumulation in cells. Five hundred Wl from 3 ml of
each lower chamber were also put into scintillation
vials and the radioactivity was measured. The apical-
to-basolateral £uxes of [3H]VBL and [14C]sucrose
were calculated as described by Takanaga et al. [27]
and Fenart et al. [28].
2.9. Densitometric and statistical analysis
All of the experiments were performed at least
three times. The intensities of the bands obtained
from the photolabeling experiment were calculated
with a Personal densitometer SI (Molecular Dynam-
ics, Sunnyvale, CA, USA). Statistical analysis was
performed using Student’s paired t-test. P6 0.05
was considered signi¢cant.
Fig. 1. Inhibition of P-gp photolabeling and transport. (A) For
P-gp photolabeling, CHRC5 cell membranes (50 Wg protein)
were incubated in the presence of 0.1% DMSO (control), 100
WM resveratrol, 30 Wg/ml green tea polyphenols (GTPs), 50 WM
verapamil, 5 WM cyclosporin A (CsA) or 5 WM PSC 833 along
with IAAP (20 nM) followed by cross-linking with UV light.
Proteins were resolved by SDS^PAGE using 6.25% polyacryl-
amide gels as described in Section 2. For the detection of pho-
tolabeled P-gp with [125I]IAAP, gels were exposed to Fuji ¢lms
at 380‡C. (B) The bands corresponding to photolabeled P-gp
were analyzed by laser densitometry. Results are presented as
the percentage of photolabeled P-gp þ S.D. in the presence of
individual agents as compared to the control (100%). One rep-
resentative experiment is shown (n = 3). (C) To study the trans-
port activity of P-gp, the accumulation of R-123 in CHRC5
cells was measured over 2 h as described in Section 2. R-123
accumulation in CHRC5 cells in the presence of 0.1% DMSO,
resveratrol (100 WM), green tea polyphenols (30 Wg/ml), verapa-
mil (50 WM), CsA (5 WM) or PSC 833 (5 WM) was measured,
and the results are expressed as a percentage of R-123 accumu-
lation in the control cells þ S.D. (n = 3).
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3. Results
3.1. E¡ect of green tea polyphenols on binding and
transport activities of P-gp
We ¢rst investigated the inhibition of P-gp photo-
labeling in resistant cells overexpressing P-gp
(CHRC5) by GTPs and resveratrol, a polyphenol
from red wine (Fig. 1A,B). Levels of photolabeled
P-gp were decreased by 40% and 75% in the presence
of resveratrol (100 WM) and GTPs (30 Wg/ml), respec-
tively. Known P-gp inhibitors verapamil (50 WM),
CsA (5 WM) and PSC 833 (5 WM) decreased the
photolabeling of P-gp by more than 90%. Increasing
the concentration of GTPs augmented the inhibition
of P-gp photolabeling (Fig. 2A,B). The concentration
of GTPs which inhibited 50% of P-gp photolabeling
was 10 Wg/ml.
The uptake of R-123, a P-gp substrate, by CHRC5
cells was used to study P-gp transport. R-123 accu-
mulation was increased in cells incubated with res-
veratrol, GTPs, verapamil, CsA and PSC 833 by 1.4-,
3.1-, 4.2-, 5.2- and 8.3-fold, respectively (Fig. 1C).
To further examine the inhibition of P-gp by GTPs,
R-123 accumulation was evaluated in the presence of
increasing concentrations of GTPs (Fig. 2C). GTPs
increased the accumulation of R-123 in CHRC5 cells
in a dose-dependent manner. At the lowest concen-
tration of GTPs used, 15 Wg/ml, R-123 accumulation
was increased 2.2-fold compared to 8.3-fold at 300
Wg/ml. At this higher concentration of GTPs, R-123
accumulation was similar to that measured in the
presence of 5 WM PSC 833, a well known and potent
P-gp inhibitor.
Following these experiments, we sought to deter-
mine whether the inhibition of P-gp transport caused
Fig. 2. Inhibition of P-gp photolabeling and transport by green
tea polyphenols. (A) CHRC5 membrane proteins (50 Wg) were
incubated with di¡erent concentrations of GTPs along with
IAAP (20 nM) and then cross-linked with UV light. Proteins
were resolved by SDS^PAGE using 6.25% polyacrylamide gels.
(B) The levels of photolabeled P-gp were estimated by laser
densitometry and expressed as a percentage of control level
(n = 3). (C) The R-123 accumulation in CHRC5 cells was mea-
sured in the presence of varying concentrations of GTPs. Re-
sults are expressed as a percentage of R-123 accumulation in
the control cells þ S.D. (n = 3).
Fig. 3. Reversibility of P-gp transport inhibition by GTPs. To
verify whether the inhibition of P-gp transport in CHRC5 by
GTPs was reversible, R-123 accumulation was measured under
standard conditions (open bars) as described in Section 2, or
after washing the cells to remove CsA or GTPs (closed bars).
CHRC5 cells were pre-incubated with 0.1% DMSO (control),
5 WM CsA or 30 and 100 Wg/ml GTPs for 30 min, washed ¢ve
times with HBSS (where applicable) and R-123 (20 WM) was
added for 2 h at 37‡C. Results are expressed as a percentage of
R-123 accumulation in the control cells þ S.D. (n = 3).
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by GTPs was reversible (Fig. 3). In this approach,
CHRC5 cells were pre-incubated with 30 or 100 Wg/
ml GTPs or 5 WM CsA for 30 min. After this pre-
incubation, cells were washed ¢ve times before the
addition of 20 WM R-123. Compared to non-washed
cells, the accumulation of R-123 in washed cells re-
turned to the control values, indicating that inhibi-
tors were removed during the washing procedures.
Thus, the inhibition of P-gp transport by GTPs, as
well as by CsA, was reversible.
3.2. E¡ects of individual catechins from green tea on
the activity of P-gp
We investigated the inhibition of P-gp photolabel-
ing and transport by the major catechins found in
green tea (Fig. 4). At a concentration of 50 WM, the
catechins C, EC and EGC decreased P-gp photolab-
eling with IAAP by 10% whereas CG, EGCG and
ECG inhibited 56%, 67% and 78% of P-gp labeling,
respectively (Fig. 4A,B). Among the catechins tested,
only ECG, CG and EGCG had an e¡ect on P-gp
transport (Fig. 4C). EGCG, CG and ECG increased
the accumulation of R-123 in CHRC5 cells by 3.7-,
2.0- and 1.5-fold, respectively. The proportions of
these three catechins in the GTPs used in the present
study were analyzed by HPLC. EGCG, ECG and
CG comprised 33%, 4.1% and less than 1% (w/w)
of GTPs, respectively, suggesting that the e¡ect of
these polyphenols on P-gp was mainly caused by
EGCG.
To further study the inhibition of P-gp transport
by EGCG, the e¥ux of R-123 was measured as a
direct representation of P-gp transport (Fig. 5). Ef-
£ux experiment was performed in order to verify that
EGCG a¡ects P-gp and not the membrane perme-
ability, since EGCG could increase R-123 accumula-Fig. 4. E¡ect of individual catechins from GTPs on P-gp pho-
tolabeling and transport. (A) CHRC5 membrane proteins (50
Wg) were incubated with 50 WM of each catechin (C, EC, EGC,
ECG, CG and EGCG) and IAAP (20 nM) followed by cross-
linking under UV light. Proteins were resolved by SDS^PAGE
using 6.25% polyacrylamide gels. (B) The levels of photolabeled
P-gp were estimated by laser densitometry and expressed as a
percentage of control level (n = 3). (C) R-123 accumulation in
CHRC5 cells was measured in the presence of 100 WM of each
catechin (C, EC, EGC, ECG, CG and EGCG). Results are ex-
pressed as a percentage of R-123 accumulation in the control
cells (n = 4).
Fig. 5. E¥ux of R-123 from CHRC5 cells. Cells were pre-incu-
bated with R-123 (20 WM) and CsA (10 WM) for 2 h followed
by three washes with HBSS. Cells were then incubated in
HBSS with 0.1% DMSO as a control (a), 100 WM EGCG (R),
10 WM CsA (b) or 10 WM PSC 833 (F). The R-123 remaining
in the CHRC5 cells was measured at intervals over 60 min
(n = 4).
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tion in CHRC5 cells by increasing membrane perme-
ability. CHRC5 cells were loaded with the £uorescent
dye, washed and the R-123 remaining in the cells was
then monitored in the presence or absence of P-gp
modulators. A diminution over time of the R-123 in
the cells indicates that R-123 was expelled from the
cells. In the presence of EGCG, like CsA and PSC
833, the R-123 remaining in CHRC5 cells was higher
than in the control cells, suggesting that EGCG de-
creased the e¥ux of R-123 by blocking P-gp.
3.3. Proliferation of CHRC5 and AuxB1 cells in the
presence of EGCG
P-gp expression in the parental sensitive cell line
(AuxB1) and the resistant cell line overexpressing P-
gp (CHRC5) was monitored by Western blots using
the mAb C219 (Fig. 6A). Immunodetection results
showed that CHRC5 cells express a higher level of
P-gp than do AuxB1 cells. These two cell lines were
used to determine the e¡ect of EGCG on cell prolif-
eration. Cells were grown for 3 days in the presence
of di¡erent concentrations of EGCG (0^50 WM)
without reaching con£uence and the crystal violet
assay was used to measure the e¡ect of this catechin
on cell growth. The proliferation of CHRC5 cells was
less a¡ected than AuxB1 cells by the presence of
EGCG (Fig. 6B). Similar results were obtained
with CHRC5 and AuxB1 cells when using 0 to 100
Wg/ml of GTPs (data not shown). Furthermore, the
combination of EGCG with VBL was tested on
CHRC5 cell proliferation to determine whether
EGCG potentiates the toxicity of the chemothera-
peutic agent VBL (Table 1). The concentration of
VBL which decreases cell growth by 50% (IC50)
was 1000 nM for CHRC5 cells and 9 nM for the
sensitive AuxB1 cells. When CHRC5 cells were
grown in the presence of VBL and 10 or 50 WM of
EGCG, the IC50 values decreased to 600 and 9 nM,
respectively.
3.4. Vinblastine transport and accumulation in
Caco-2 cells
Human intestinal adenocarcinoma cells (Caco-2),
which form an epithelial monolayer, are often used
as a model for intestinal transport studies mediated
by P-gp. [3H]VBL £ux across the intestinal barrier is
represented by the passage of [3H]VBL, a P-gp sub-
strate, from the apical compartment towards the ba-
solateral side. After 2 h incubation the amount of
[3H]VBL was measured in the lower chamber of
the well, which corresponds to the basolateral side.
Fig. 6. Proliferation of CHRC5 and AuxB1 cells in the presence
of EGCG. (A) Immunodetection of P-gp in AuxB1 (20 Wg of
protein) and CHRC5 (2 Wg) cells by Western blot. (B) AuxB1
(a) and CHRC5 (b) cells were grown at subcon£uence in the
presence of 0^50 WM EGCG. The crystal violet assay was used
to measure the proliferation of cells as described in Section 2
(n = 3).
Table 1
Proliferation of AuxB1 and CHRC5 cells in the presence of vin-
blastine
EGCG (WM) IC50 for vinblastine (nM)
AuxB1 0 9 þ 4
CHRC5 0 1000 þ 200
10 600 þ 100
50 9 þ 5
AuxB1 and CHRC5 cells were grown at subcon£uence in the
presence of VBL and the concentration (IC50) of VBL for
which cell growth was decreased by 50% was determined. In
addition to VBL, CHRC5 cells were incubated with 10 and 50
WM EGCG. Crystal violet assay was used to measure cell pro-
liferation (n = 3).
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EGCG (100 WM) and the P-gp inhibitor PSC 833 (10
WM) each increased by 2.6-fold the apical-to-basal
£ux of [3H]VBL across the Caco-2 cell monolayer
(Fig. 7A) and increased the accumulation of
[3H]VBL within the cells by 2.2- and 3.4-fold, respec-
tively (Fig. 7B). Indomethacin (10 WM), a MRP in-
hibitor, did not increase the [3H]VBL £ux and the
intracellular accumulation. The passage of [3H]VBL
across Caco-2 cells exposed to EGCG was not fur-
ther increased when indomethacin was present along
with EGCG. The permeability coe⁄cient for the ap-
ical-to-basolateral passage of [14C]sucrose across the
Caco-2 cell monolayer was also measured. Under all
conditions of this experiment, the permeability coef-
¢cient was the same (0.45 þ 0.02U1033 cm/min), in-
dicating that the integrity of the monolayer barrier
was una¡ected by P-gp and MRP modulators. Thus,
the passage of [3H]VBL through the intestinal barrier
and its uptake into cells were both increased by the
presence of EGCG without a¡ecting the integrity of
this barrier.
4. Discussion
For a long time, green tea has been a popular
beverage in many countries, and epidemiological
studies have suggested that its consumption is asso-
ciated with a lower risk of cancer [20^22]. A great
interest is growing in order to understand the molec-
ular mechanisms of the biological e¡ects associated
with green tea and its major constituents. Most of
the actions associated with green tea are due to cat-
echins, the main polyphenols of green tea [20^24]. It
has recently been reported that green tea increased
the availability of P-gp substrate in tumor [22]. On
the other hand, it has also been reported that some
catechins were absorbed faster then others after oral
administration of green tea [29]. P-gp is expressed in
the intestine and could be in part responsible for
limiting the intestinal absorption. Thus, in the
present study, we decided to investigate whether
GTPs modulate the multidrug resistance transporter
P-gp activity and to determine which of the catechins
were implicated.
The ability of GTPs to interact at the substrate
binding site of P-gp and to modulate its transport
activity were ¢rst determined. GTPs bind to P-gp,
as shown by photoa⁄nity labeling of P-gp with
IAAP, which was previously used to monitor the
pharmacological interactions between P-gp and var-
ious compounds such as verapamil, cyclosporin A
and PSC 833 [30]. Moreover, GTPs inhibit the trans-
port of the P-gp substrates R-123 and VBL, suggest-
ing that a component present in GTPs could be car-
ried by this transporter. Furthermore, the binding of
GTPs to P-gp in addition to the data regarding the
accumulation and e¥ux of R-123 support the hy-
pothesis that GTPs modulate P-gp activity rather
than a modi¢cation of the membrane permeability.
Fig. 7. Inhibition of vinblastine transport in Caco-2 cells by
EGCG. (A) Caco-2 cells were used to measure apical-to-basal
transport of [3H]VBL in the presence of 0.1% DMSO (control),
100 WM EGCG, 10 WM PSC 833, 10 WM indomethacin (Indo)
or a combination of 100 WM EGCG with 10 WM indomethacin
(Indo+EGCG). Apical-to-basolateral £ux of [3H]VBL was cal-
culated as previously described in Section 2. (B) [3H]VBL accu-
mulation in Caco-2 cells was measured by recovering the ¢lters
containing the cells exposed to 100 WM EGCG, 10 WM PSC
833, 10 WM indomethacin or 100 WM EGCG with 10 WM indo-
methacin and comparing radiolabel content to that found in
the control samples (100%) (n = 4).
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Among the catechins present in GTPs, the three cat-
echin gallate esters EGCG, ECG and CG signi¢-
cantly inhibit both the binding and transport activ-
ities of P-gp, where EGCG is the most potent P-gp
modulator.
Since EGCG is the principal catechin in green tea
as well as that which most strongly a¡ects P-gp
transport, we concentrated our study on this cate-
chin. In the presence of EGCG, the growth of
CHRC5 cells was less a¡ected than were AuxB1 cells,
suggesting that the overexpression of P-gp in CHRC5
cells may play an important role in the protection of
these cells against EGCG by transporting this cate-
chin out of the cells. In addition, our results show
that EGCG can increase the e⁄cacy of cancer che-
motherapeutic drugs. When CHRC5 cells were ex-
posed to the chemotherapeutic agent VBL in combi-
nation with EGCG, the IC50 of VBL for these cells
was the same as the IC50 for VBL alone in AuxB1
cells. This result indicates that EGCG potentiates the
toxicity of VBL in CHRC5 cells which overexpress P-
gp, and sensitizes these cells to anticancer drugs to
the level found in the drug sensitive AuxB1 cells.
Moreover, P-gp inhibition by GTPs is a rapid revers-
ible process, in contrast to that seen with PSC 833
[31]. Since P-gp has many physiological functions in
normal tissues, inhibition of this multidrug trans-
porter during cancer chemotherapy should be rapid
and reversible in order to reduce undesirable side
e¡ects. Taken together, these results suggest that
EGCG could be used to inhibit P-gp in cancer cells,
and further in vivo studies are required in order to
verify this possibility. Many other biological e¡ects
of EGCG have been reported, such as inhibition of
tumoral cell growth, induction of apoptosis and in-
hibition of urokinase and matrix metalloproteinase
(MMP-2, MMP-9 and MMP-12) activities [22,32^
34]. These actions are important in promoting tumor
reduction and reducing metastasis formation. Thus,
many bene¢cial actions are associated with the nat-
ural compound EGCG.
EGCG has been reported to be weakly absorbed
by the intestine [29]. Since our results suggest that
EGCG is a substrate of P-gp, the Caco-2 model was
used to verify whether P-gp could be partly respon-
sible for the low intestinal absorption of this cate-
chin. The Caco-2 cell line is a well-established intes-
tinal transport model which forms a polarized
epithelial cell monolayer and expresses P-gp at the
apical membrane [35]. Apical-to-basolateral trans-
port of VBL in this model allowed us to study the
e¡ect of the apical P-gp on the passage of P-gp sub-
strates across the intestinal barrier. Apical-to-baso-
lateral transport of VBL across this intestinal cell
monolayer was inhibited by EGCG, suggesting that
P-gp transport could explain why EGCG is weakly
absorbed by the intestine. In fact, only 0.1% of
EGCG was reported to be bioavailable after an in-
tragastric administration of green tea, compared to
13.7% and 31.2% for EGC and EC [29]. These two
catechins are not transported by P-gp, as suggested
from our binding and transport studies. Thus, P-gp
in the apical membranes of intestinal cells may re-
duce absorption of EGCG by transporting this cat-
echin back into the lumen of the intestine. Further-
more, this result indicates that administration routes
other than the oral one seem to be necessary in order
to increase its plasma concentration.
Caco-2 cells also express members of the multidrug
resistance-associated protein (MRP) family including
MRP1, MRP2, MRP3 and MRP5 [36]. These trans-
porters were shown to play a minor part in the baso-
lateral-to-apical e¥ux of VBL through Caco-2 cells
[37]. In addition, it was reported that CsA and PSC
833 are weak inhibitors of MRP1-mediated transport
[38]. Thus, in the present apical-to-basolateral trans-
port experiments of VBL, PSC 833 was used at a
concentration (10 WM) that does not inhibit MRP-
related transport. This £ux of VBL, which corre-
sponds to its intestinal absorption, was increased
by PSC 833 but not by indomethacin, an inhibitor
of MRPs [39]. These results indicate that the apical-
to-basolateral passage of VBL across Caco-2 cells
was mediated mainly by P-gp and suggests that
MRP transporters were not involved. However, we
cannot rule out the possibility that EGCG may in-
teract with other MDR-related transporters than P-
gp. Along related lines, a recent study has shown
that MRP1 transport and ATPase activities were
modulated by dietary £avonoids [40] such as querce-
tin, which have also been reported to inhibit P-gp
transport [41].
Other compounds derived from natural products
have been reported to inhibit P-gp. Our results show
that resveratrol, a polyphenol from red wine, inter-
acts with P-gp. Curcumin, genistein, ca¡eine, thea-
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nine, components of fruit juices, such as quercetin,
naringin and furanocoumarins from grapefruit and
methoxy£avones from orange, were shown to inhibit
drug transport via P-gp [27,41^45]. Taken together,
these results suggest that compounds derived from
natural dietary products can modulate the activity
of this transporter in vivo. Moreover, during oral
chemotherapy, the diet of patients may in£uence
the e⁄cacy of therapy using P-gp substrates, suggest-
ing that cancer treatment planning must take into
account the diet of each patient.
Our results show that GTPs interact with P-gp and
inhibit the transport activity of this enzyme by a re-
versible manner in CHRC5 cells. Among the cate-
chins present in green tea leaves, EGCG was the
most potent inhibitor of P-gp. In addition, we found
that intestinal P-gp could be responsible for the low
absorption of EGCG. Our results suggest that GTPs,
and especially EGCG, could improve the e⁄cacy of
cancer treatment by increasing the accumulation of
chemotherapeutic drugs in cancer cells by blocking
P-gp function. Further studies are required to eval-
uate in vivo the e¡ect of polyphenols from green tea
or the catechin EGCG, on the multidrug resistance
associated with P-gp during chemotherapy.
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